

Taiwan's iXensor receives strategic investment to expand mobile health biz globally

28 April 2022 | News

Japan-based Rohto Pharmaceutical will deploy iXensor's patented PixoTech technology to digitize its new products

Taiwan's iXensor, the pioneer of mobile health, has announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech platform licensing business.

Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech technology to digitize its new products through a separate technology licensing and joint development agreement, thereby providing Rohto Pharmaceutical's consumers with innovative self-testing portfolios including women's health and infectious diseases in Japan market.

iXensor's first product, PixoTest Glucose Monitoring System, developed based on its PixoTech platform, is the world's first US FDA-approved smartphone camera-based blood test dated in 2017.

The PixoTech, currently protected by more than 70 international patents, is iXensor's core technology platform that transforms smartphones into in vitro diagnostic instruments for biomedical analysis in point-of-care testing and self-testing. PixoTech[®] controls smartphones' camera sensing modules and screen lighting emissions with multiple wavelengths to analyze all types of immunoassay and enzymatic tests through the proprietary algorithm.